DGAP-News: Oxford Immunotec /
Oxford Immunotec Schedules Fourth Quarter and Full Year 2013 Earnings
Release and Conference Call for March 4, 2014

24.02.2014 / 19:41

---------------------------------------------------------------------

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2014-02-24 19:41 CET (GLOBE
NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to
release fourth quarter and full year 2013 financial results prior to market
open on Tuesday, March 4, 2014. Dr. Peter Wrighton-Smith, Chief Executive
Officer and Rick Altieri, Chief Financial Officer will host a conference call
to review the Company's results at 8:00am Eastern Time the same day. The call
will be concurrently webcast. 

To listen to the conference call on your telephone, please dial (855) 363-5047
for United States callers and +1 (484) 365-2897 for international callers and
reference confirmation code 2444858, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec's website at
http://www.oxfordimmunotec.com. The replay will be available on the Company's
website for approximately 90 days. 

Notes to Editors:

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT(r) technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system,
and are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune
diseases. The Company's initial product developed using the T-SPOT technology
platform is the T-SPOT.TB test, which is used to test for latent tuberculosis
infection. The T-SPOT.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market approval from the
Food and Drug Administration, Europe, where it has obtained a CE mark, as well
as Japan and China. The Company is headquartered near Oxford, UK and in
Marlborough, MA. Additional information can be found at
www.oxfordimmunotec.com. 

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.



CONTACTS:                    
                             
For Media Inquiries:         
Caroline Crawley             
Oxford Immunotec             
Tel: +44 1235 442796         
ccrawley@oxfordimmunotec.com 
                             
For Investor Inquiries:      
Rick Altieri                 
Chief Financial Officer,     
Oxford Immunotec             
Tel: +1 (508) 481-4648       
raltieri@oxfordimmunotec.com 
                             
Mark Klausner                
Westwicke Partners           
Tel: +1 (443) 213-0500       
oxfordimmunotec@westwicke.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

24.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English           
Company:     Oxford Immunotec  
 
 
             United Kingdom    
ISIN:        GB00BGFBB958      
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
254060 24.02.2014